Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Return on Sales (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Return on Sales data on record, last reported at 98.99% in Q4 2025.

  • For Q4 2025, Return on Sales changed N/A year-over-year to 98.99%; the TTM value through Dec 2025 reached 98.99%, changed N/A, while the annual FY2023 figure was 37.75%, 3071.0% down from the prior year.
  • Return on Sales reached 98.99% in Q4 2025 per RVMD's latest filing, up from 26.71% in the prior quarter.
  • Across five years, Return on Sales topped out at 98.99% in Q4 2025 and bottomed at 765.3% in Q3 2024.
  • Average Return on Sales over 5 years is 106.81%, with a median of 9.71% recorded in 2023.
  • Peak YoY movement for Return on Sales: crashed -75262bps in 2024, then soared 79201bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 5.57% in 2021, then skyrocketed by 33bps to 3.71% in 2022, then crashed by -5791bps to 218.77% in 2023, then tumbled by -250bps to 765.3% in 2024, then skyrocketed by 113bps to 98.99% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 98.99% in Q4 2025, 26.71% in Q3 2025, and 765.3% in Q3 2024.